CARSCADDEN GWEN R. 4
4 · Intersect ENT, Inc. · Filed Feb 5, 2020
Insider Transaction Report
Form 4
CARSCADDEN GWEN R.
Chief People Officer
Transactions
- Award
Common Stock
2020-02-03+6,690→ 24,396 total - Award
Common Stock
2020-02-03+6,690→ 31,086 total - Award
Stock Options (Right to buy)
2020-02-03+13,250→ 13,250 totalExercise: $26.18Exp: 2030-02-03→ Common Stock (13,250 underlying)
Footnotes (5)
- [F1]Represents restricted stock units granted pursuant to the Intersect ENT, Inc. 2014 Equity Incentive Plan. Each restricted stock unit represents a right to receive one share of Intersect ENT, Inc. common stock upon vesting. The restricted stock units shall vest on the third anniversary from the date of grant provided that certain 30-day trailing average stock price (the "Average Closing Price") targets are achieved at any time during the three year period following the date of grant. 33 1/3%, 66 2/3% or 100% of the shares will vest if the Average Closing Price equals or exceeds specific stock price targets.
- [F2]Includes 11,457 restricted stock units, of which 6,690 are performance based.
- [F3]Represents restricted stock units granted pursuant to the Intersect ENT, Inc. 2014 Equity Incentive Plan. Each restricted stock unit represents a right to receive one share of Intersect ENT, Inc. common stock upon vesting. The restricted stock units vest in three equal annual installments commencing one year after the grant date.
- [F4]Includes 18,147 restricted stock units, of which 6,690 are performance based.
- [F5]The vesting commencement date of the option is February 3, 2020. 1/8th of the shares subject to the option shall vest on August 3, 2020 and 1/48th of the shares subject to the option shall vest monthly thereafter over 42 months.